Strasbourg, France

Claude Bauder

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 19(Granted Patents)


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Claude Bauder: Innovator in Pharmaceutical Chemistry

Introduction

Claude Bauder is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel methods for synthesizing important compounds.

Latest Patents

One of his key patents is titled "Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping." This patent discloses a novel method for preparing these compounds using innovative reaction intermediates. The patent highlights the importance of these compounds in the pharmaceutical industry, particularly for their potential therapeutic applications.

Career Highlights

Throughout his career, Claude Bauder has focused on advancing the methodologies used in pharmaceutical synthesis. His work has led to the development of more efficient processes that can enhance the production of vital compounds. His dedication to innovation in this field has earned him recognition among his peers.

Collaborations

Claude has collaborated with various professionals in the industry, including his coworker Guy Solladie. These collaborations have fostered an environment of shared knowledge and innovation, contributing to the advancement of their respective fields.

Conclusion

Claude Bauder's contributions to pharmaceutical chemistry through his innovative patent and collaborative efforts underscore his role as a significant inventor in the industry. His work continues to influence the development of important pharmaceutical compounds.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…